

**Table S1** Collinear analysis of potential risk factors.

<b>Variables</b>	<b>Tolerance</b>	<b>VIF</b>
CDM adherence	0.926	1.08
Age	0.78	1.282
Hb	0.716	1.397
Scr	0.182	5.489
eGFR	0.151	6.618
Urea	0.697	1.435
CKD Stage	0.141	7.093
UA	0.927	1.079
CO <sub>2</sub> CP	0.815	1.227
BLD	0.85	1.177
PRO	0.706	1.417
Primary disease	0.81	1.234
Hypertension	0.573	1.745
Cardiovascular disease	0.867	1.154
Diuretics	0.847	1.181
ACEI/ARB	0.784	1.275
CCB	0.564	1.773
Alpha-blockers	0.813	1.23
Beta-blockers	0.763	1.311
Sodium bicarbonate	0.819	1.221

EPO	0.563	1.777
Polysaccharide-Iron Complex	0.565	1.768
Folic acid	0.705	1.418
Compound $\alpha$ -ketoacid Tablets	0.851	1.175
Calcium supplement	0.886	1.128
Chinese herbal decoction	0.98	1.021
Chinese patent medicines for dispelling turbidity	0.781	1.281

Abbreviations: CDM: chronic disease management; Hb: hemoglobin; Scr: serum creatinine; eGFR: estimated glomerular filtration rate; UA: serum uric acid; CO<sub>2</sub>CP: carbon dioxide combining power; BLD: urine latent blood; PRO: urine protein; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blockers; CCB: calcium channel entry blockers; EPO: erythropoietin

**Table S2** Models' net reclassification improvement and integrated discrimination improvement

	Year	NRI (95% CI)	IDI (95% CI)	P Value
Model B vs. Model E	1	-0.359 (-0.683, 0.037)	-0.071 (-0.128, -0.021)	<0.001
	2	-0.332 (-0.568, -0.035)	-0.067 (-0.110, -0.014)	<0.001